49 research outputs found
Matrix and Stimulus Sample Sizes in the Weighted MDS Model: Empirical Metric Recovery Functions
The only guidelines for sample size that exist in the multidimensional scaling (MDS) literature are a set of heuristic "rules-of-thumb" that have failed to live up to Young's (1970) goal of finding func tional relationships between sample size and metric recovery. This paper develops answers to two im portant sample-size questions in nonmetric weight ed MDS settings, both of which are extensions of work reported in MacCallum and Cornelius (1977): (1) are the sample size requirements for number of stimuli and number of matrices compensatory? and (2) what type of functional relationships exist between the number of matrices and metric recov ery ? The graphs developed to answer the second question illustrate how such functional relation ships can be defined empirically in a wide range of MDS and other complicated nonlinear models.Yeshttps://us.sagepub.com/en-us/nam/manuscript-submission-guideline
Plasma hydroxy-metronidazole/ metronidazole ratio in hepatitis C virus-induced liver disease
Gallbladder Management during Laparoscopic Roux-en-Y Gastric Bypass Surgery: Routine Preoperative Screening for Gallstones and Postoperative Prophylactic Medical Treatment are Not Necessary
Endoscopic Retrograde Cholangiopancreatography after Laparoscopic Roux-en-Y Gastric Bypass: A Case Series and Review of the Literature
Recommended from our members
499 The impact of sustained virological response (SVR) on health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2A (PEGASYS®) and ribavirin (COPEGUS®)
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
HCV infects approximately 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the association of this therapy with frequent and, at times, serious adverse effects. Recognition and effective management of these adverse effects are critical components of the successful treatment of chronic HCV infection. In clinical trials, approximately 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clinical practice, the rate of treatment discontinuation has been reported to be substantially higher. The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematologic, dermatologic, neurologic, immunologic, gastrointestinal, pulmonary, cardiovascular, and ocular. Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact. This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects. © 2011 Macmillan Publishers Limited. All rights reserved
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
HCV infects approximately 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the association of this therapy with frequent and, at times, serious adverse effects. Recognition and effective management of these adverse effects are critical components of the successful treatment of chronic HCV infection. In clinical trials, approximately 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clinical practice, the rate of treatment discontinuation has been reported to be substantially higher. The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematologic, dermatologic, neurologic, immunologic, gastrointestinal, pulmonary, cardiovascular, and ocular. Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact. This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects. © 2011 Macmillan Publishers Limited. All rights reserved
Recommended from our members